These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 29132915)

  • 1. Human recombinant erythropoietin reduces sensorimotor dysfunction and cognitive impairment in rat models of chronic kidney disease.
    Reza-Zaldívar EE; Sandoval-Avila S; Gutiérrez-Mercado YK; Vázquez-Méndez E; Canales-Aguirre AA; Esquivel-Solís H; Gómez-Pinedo U; Márquez-Aguirre AL
    Neurologia (Engl Ed); 2020 Apr; 35(3):147-154. PubMed ID: 29132915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia.
    Garrido P; Ribeiro S; Fernandes J; Vala H; Rocha-Pereira P; Bronze-da-Rocha E; Belo L; Costa E; Santos-Silva A; Reis F
    Int J Mol Sci; 2015 Dec; 17(1):. PubMed ID: 26712750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between abnormal GSK3β, β Amyloid, total Tau, p-Tau 181 levels and neuropsychological assessment total scores in CKD patients with cognitive dysfunction: Impact of rHuEPO therapy.
    Vinothkumar G; Krishnakumar S; Riya ; Venkataraman P
    J Clin Neurosci; 2019 Nov; 69():38-42. PubMed ID: 31447360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose.
    Ribeiro S; Garrido P; Fernandes J; Vala H; Rocha-Pereira P; Costa E; Belo L; Reis F; Santos-Silva A
    Clin Exp Pharmacol Physiol; 2016 Mar; 43(3):343-54. PubMed ID: 26889660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia.
    Ribeiro S; Garrido P; Fernandes J; Vala H; Rocha-Pereira P; Costa E; Belo L; Reis F; Santos-Silva A
    Biochimie; 2016 Jun; 125():150-62. PubMed ID: 27039028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic impact of rHuEPO on abnormal platelet APP, BACE 1, presenilin 1, ADAM 10 and Aβ expressions in chronic kidney disease patients with cognitive dysfunction like Alzheimer's disease: A pilot study.
    G V; S K; Sureshkumar ; G S; S S; Preethikrishnan ; S D; A S; D B; Riya ; P V
    Biomed Pharmacother; 2018 Aug; 104():211-222. PubMed ID: 29775888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia?
    Eschbach JW; Varma A; Stivelman JC
    Nephrol Dial Transplant; 2002; 17 Suppl 5():2-7. PubMed ID: 12091599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impacts of recombinant human erythropoietin treatment during predialysis periods on the progression of chronic kidney disease in a large-scale cohort study (Co-JET study).
    Akizawa T; Saito A; Gejyo F; Suzuki M; Nishizawa Y; Tomino Y; Tsubakihara Y; Akiba T; Hirakata H; Watanabe Y; Kawanishi H; Bessho M; Udagawa Y; Aoki K; Uemura Y; Ohashi Y;
    Ther Apher Dial; 2014 Apr; 18(2):140-8. PubMed ID: 24720404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
    Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats.
    Kato S; Takahashi T; Miyata N; Roman RJ
    J Pharmacol Exp Ther; 2020 Feb; 372(2):166-174. PubMed ID: 31801803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-erythropoietin-based anaemia management in chronic kidney disease.
    Hörl WH
    Nephrol Dial Transplant; 2002; 17 Suppl 11():35-8. PubMed ID: 12386256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Zinc Supplementation on Renal Anemia in 5/6-Nephrectomized Rats and a Comparison with Treatment with Recombinant Human Erythropoietin.
    Feng HL; Chen YH; Jeng SS
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31600973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Predialysis Recombinant Human Erythropoietin on Early Survival After Hemodialysis Initiation in Patients With Chronic Kidney Disease: Co-JET Study.
    Watanabe Y; Akizawa T; Saito A; Gejyo F; Suzuki M; Nishizawa Y; Tomino Y; Tsubakihara Y; Akiba T; Hirakata H; Kawanishi H; Bessho M; Udagawa Y; Aoki K; Uemura Y; Ohashi Y;
    Ther Apher Dial; 2016 Dec; 20(6):598-607. PubMed ID: 27928910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver iron is a major regulator of hepcidin gene expression via BMP/SMAD pathway in a rat model of chronic renal failure under treatment with high rHuEPO doses.
    Ribeiro S; Garrido P; Fernandes J; Rocha-Pereira P; Costa E; Belo L; Reis F; Santos-Silva A
    Biofactors; 2016 May; 42(3):296-306. PubMed ID: 26990350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia.
    Landau D; London L; Bandach I; Segev Y
    PLoS One; 2018; 13(5):e0196684. PubMed ID: 29738538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis.
    Cody JD; Hodson EM
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD003266. PubMed ID: 26790135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to erythropoietin in pediatric patients with chronic kidney disease: insights from an in vitro bioassay.
    Gavish R; Watad S; Ben-Califa N; Goldberg OJ; Haskin O; Davidovits M; Koren G; Falush Y; Neumann D; Krause I
    Pediatr Nephrol; 2018 Nov; 33(11):2123-2129. PubMed ID: 30030607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients.
    Lui SF; Wong KC; Li PK; Lai KN
    Am J Nephrol; 1992; 12(1-2):55-60. PubMed ID: 1415366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant Erythropoietin Provides Protection against Renal Fibrosis in Adenine-Induced Chronic Kidney Disease.
    Vázquez-Méndez E; Gutiérrez-Mercado Y; Mendieta-Condado E; Gálvez-Gastélum FJ; Esquivel-Solís H; Sánchez-Toscano Y; Morales-Martínez C; Canales-Aguirre AA; Márquez-Aguirre AL
    Mediators Inflamm; 2020; 2020():8937657. PubMed ID: 32184703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteration of mRNA expression of molecules related to iron metabolism in adenine-induced renal failure rats: a possible mechanism of iron deficiency in chronic kidney disease patients on treatment.
    Hamada Y; Kono TN; Moriguchi Y; Higuchi M; Fukagawa M
    Nephrol Dial Transplant; 2008 Jun; 23(6):1886-91. PubMed ID: 18174266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.